JPRN-UMIN000026954招募中2 期
Feasibility study of dose dense chemotherapy for primary breast cancer patients - Feasibility study of dose dense chemotherapy for primary breast cancer patients
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1. Active multiple primary cancer (synchronous multiple primary cancer and invasive cancer of other organs) 2. History of drug-related allergy which could hinder planned treatment 3. Any history or complication of following cardiac disorders - History of congestive heart failure, cardiac infarction - Complication requires treatment such as: ischemic cardiac disorder, arrhythmia, valvular heart disease 4. Poorly controlled hypertension 5. Poorly controlled diabetes 6. Pregnancy 7. Ineligible to the trial based on decision of an investigator
研究者
相似试验
已完成
2 期
Feasibility study of S-1 and CDDP chemotherapy with short hydration for advanced Gastric Canceradvanced and/or recurrent gastric cancerJPRN-UMIN000007409PO Japan Southwest Oncology Research Support Organization (JSWOG)50
招募中
2 期
Feasibility study of agjuvant chemotherapy with docetaxel, cisplatin and fluorouracil for esophageal canceresophageal cancerJPRN-UMIN000009150Shimane University Hospital50
招募中
1 期
A Phase I/II study of systemic chemotherapy with Docetaxel, Oxaliplatin, and S-1 followed by surgery in locally advanced adenocarcinoma of the esophagogostric junctiolocally advanced adenocarcinoma of the esophagogastric junctionJPRN-UMIN000022210Kitasato University School of Medicine40
招募中
不适用
A feasibility study of chemotherapy with vinorelbine plus bevacizumab in elderly patients with non-small lung canceron-small cell lung cancerJPRN-UMIN000005800Toho University Omori Medical Center15
进行中（未招募）
不适用
Treatment With Chemotherapy and Antiretroviral Therapy in Patients With Diffuse Large B Cell Lymphoma and Infection With the Human Immunodeficiency Virus (HIV)Diffuse Large B Cell Lymphoma and HIV InfectionEUCTR2006-003750-23-ESFundación PETHEMA